سعر Andoflozin XR 12.5/1000 mg 20 film-coated extended-release tablets 2026

Extended-release film-coated tablets combining empagliflozin 12.5 mg (SGLT2 inhibitor) and metformin hydrochloride 1000 mg (biguanide), by Al Andalous Pharmaceutical Industries; 20 tablets per pack.

• Glycaemic control in adults with type 2 diabetes mellitus (adjunct to diet and exercise); empagliflozin component: reduction of CV death, heart-failure hospitalisation and CKD progression risks in adults with T2DMPopulation: Adults with type 2 diabetesDailyMed (U.S. National Library of Medicine)
• Type 2 diabetes mellitus in adults when diet and exercise plus the individual components do not provide adequate glycaemic controlPopulation: AdultsAl Andalous Pharmaceutical Industries (manufacturer website)

• Empagliflozin: urinary tract infections and female genital mycotic infections are the most common adverse reactions.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Metformin: diarrhoea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia and headache are among the most common adverse reactions.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease or dialysis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to empagliflozin, metformin or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - lactic acidosis: post-marketing metformin-associated lactic acidosis, sometimes fatal; risk factors include renal impairment, iodinated contrast, surgery, hypoxic states, excessive alcohol and hepatic impairment. Discontinue if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Ketoacidosis (including euglycaemic) has been reported with SGLT2 inhibitors; assess patients with signs of acidosis regardless of glucose; consider temporary withholding before surgery (at least 3 days) or prolonged fasting.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Volume depletion/hypotension, urosepsis and pyelonephritis, genital mycotic infections, necrotising fasciitis of the perineum (Fournier's gangrene), hypoglycaemia with insulin or insulin secretagogues, lower-limb amputation, hypersensitivity reactions and vitamin B12 deficiency (monitor).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Carbonic anhydrase inhibitors (e.g., topiramate, zonisamide, acetazolamide)May increase the risk of lactic acidosis; consider more frequent monitoring.DailyMed (U.S. National Library of Medicine)
• Drugs that reduce metformin clearance (e.g., ranolazine, vandetanib, dolutegravir, cimetidine)Increase metformin exposure and lactic acidosis risk; consider benefits and risks.DailyMed (U.S. National Library of Medicine)
• Insulin or insulin secretagogues (e.g., sulfonylureas)Increased risk of hypoglycaemia; a lower dose of insulin or the secretagogue may be required.DailyMed (U.S. National Library of Medicine)

• Not recommended during the second and third trimesters of pregnancy (animal data with empagliflozin showed adverse renal effects during a period corresponding to late human renal development).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is not recommended while taking the product.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Empagliflozin: Inhibits SGLT2 in the proximal renal tubule, reducing renal reabsorption of filtered glucose and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion (US label).
• Metformin hydrochloride: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; insulin secretion remains unchanged (US label).